Chronos Imaging has secured the sale and shipment of 100 CT X-ray tubes from the Dunlee CT tube facility in Aurora, Illinois.
The diagnostics imaging manufacturer rang up its 100th milestone in late May, less than three months after
acquiring the CT tube manufacturing plant from Philips.
“There is high demand for high-quality CT replacement tubes that our facility has a reputation for bringing to the marketplace,” Rudy Piskule, Chronos sales operation and marketing manager, told HCB News. “We will continue to move quickly to address the needs of market. We have a strong order book and a healthy pipeline.”
Focusing on operational efficiency and yield optimization, Chronos began ramping up production at the Aurora location within weeks of the acquisition, while also implementing a new framework for the quality and regulatory systems within the organization.
The company has obtained its FDA license along with 13 local, state and federal licenses and its ISO 13485 certification.
As part of negotiations with Philips, Chronos agreed to continue to provide the Dutch-based OEM with CT tubes on a long-term supply basis while developing other tubes to serve the entire OEM and replacement CT tube marketplace.
The acquisition also included the existing (formerly Dunlee) employees and 100 percent of the functional leadership team, individuals who Piskule credits with helping Chronos ramp up production and sales in a relatively short period of time.
“Chronos Imaging has an unmatched experience set and team of experts in manufacturing complex CT tube technologies that we are not only leveraging to support our current product portfolio but, perhaps most importantly, will be utilized to rapidly introduce new innovations in line with our R&D and product roadmap,” he said. “We will continue to push improvements in yield, operating efficiency, quality and cost streamlining in conjunction with our R&D, engineering and supply chain teams, given the increasingly high expectations of customers and an aggressive competitive landscape.”
Positive revenue earnings with robust customer demand are expected, according to Chronos, based on the new business pipeline and strong forward order book.